Drug Type Biological products |
Synonyms i2o 105s |
Target |
Mechanism GLP-1R modulators(Glucagon-like peptide 1 receptor modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization I2o Therapeutics, Inc.Startup |
Active Organization I2o Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Preclinical | US | I2o Therapeutics, Inc.Startup | 27 Sep 2023 |
Nonalcoholic Steatohepatitis | Preclinical | US | I2o Therapeutics, Inc.Startup | 27 Sep 2023 |
Obesity | Preclinical | US | I2o Therapeutics, Inc.Startup | 27 Sep 2023 |